These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 16989638

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Neutralizing antibody responses to HIV-1 infection.
    Morris L.
    IUBMB Life; 2002; 53(4-5):197-9. PubMed ID: 12120994
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [The quest for an HIV vaccine].
    Girard MP.
    Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.
    Nature; 2007 Sep 06; 449(7158):101-4. PubMed ID: 17805298
    [Abstract] [Full Text] [Related]

  • 11. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL.
    Nat Rev Immunol; 2006 Dec 06; 6(12):930-9. PubMed ID: 17124514
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, Birx DL, Michael NL, McCutchan FE, Polonis VR.
    Virology; 2008 Jun 05; 375(2):529-38. PubMed ID: 18433824
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Current approaches to developing a preventative HIV vaccine.
    Tonini T, Barnett S, Donnelly J, Rappuoli R.
    Curr Opin Investig Drugs; 2005 Feb 05; 6(2):155-62. PubMed ID: 15751738
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies.
    Alving CR, Beck Z, Karasavva N, Matyas GR, Rao M.
    Mol Membr Biol; 2006 Feb 05; 23(6):453-65. PubMed ID: 17127618
    [Abstract] [Full Text] [Related]

  • 18. IgM, not IgG, a key for HIV vaccine.
    Yang QE.
    Vaccine; 2009 Feb 25; 27(9):1287-8. PubMed ID: 19146899
    [Abstract] [Full Text] [Related]

  • 19. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.
    AIDS; 2007 Mar 30; 21(6):693-702. PubMed ID: 17413690
    [Abstract] [Full Text] [Related]

  • 20. Antibodies, viruses and vaccines.
    Burton DR.
    Nat Rev Immunol; 2002 Sep 30; 2(9):706-13. PubMed ID: 12209139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.